Belgian biotech AgomAb Therapeutics NV has filed for an initial public offering in the United States. The company plans to use the capital raised to advance clinical trials for its pipeline of drugs targeting immune and inflammation diseases. This move signals a key step in its growth strategy.

IPOs provide biotech firms with crucial funding for expensive, late-stage trials that can take years and cost hundreds of millions. For AgomAb, this public listing could accelerate development of its experimental therapies. The company joins a wave of European biotechs seeking U.S. investor capital to compete globally.

Investors will watch the IPO pricing and subsequent trial results. Success in its lead programs could validate AgomAb's platform and attract further investment. The filing places the company under greater scrutiny, requiring transparent progress updates to maintain market confidence as it navigates regulatory hurdles.